Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CD40-INN

Financiado

CD40 goes innate defining and targeting CD40 signaling intermediates in the mac...

CD40 goes innate defining and targeting CD40 signaling intermediates in the macrophage to treat atherosclerosis Atherosclerosis, the underlying cause of the majority of cardiovascular diseases (CVD), is a lipid driven, inflammatory disease of the large arteries. Despite a 25% relative risk reduction achieved by lipid-lowering treatment, the... ver más

30/11/2023

LMU MUENCHEN

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-11-30

ERC-CoG-2015: ERC Consolidator Grant

I+D

Cerrada hace 9 años

0% 100% 100%

3 Participantes

LMU MUENCHEN

399.88K€ | Lider

LODOSA AUXILIAR DEL CALZADO

STICHTING AMSTERDAM UMC

1.60M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2009-08692 INTERACCIONES ENTRE RECEPTORES TIPO TOLL Y RECEPTORES DE ESF... 157K€ Cerrado

SAF2017-82436-R MODULACION INMUNOMETABOLICA DEL MACROFAGO A TRAVES DE MTOR Y... 303K€ Cerrado

PID2020-116498RB-I00 DESCIFRANDO EL PAPEL DE NUEVOS MEDIADORES INFLAMATORIOS DERI... 238K€ Cerrado

EXPLOSIA EXpansion and Phenotype Loss Of SMCs In Atherosclerosis Cau... 2M€ Cerrado

PID2020-119030RJ-I00 SUCCINATO COMO NUEVA MOLECULA DE SEÑALIZACION EXTRACELULAR E... 198K€ Cerrado

SAF2011-30308 INTERACCIONES DE LOS PROGENITORES MESENQUIMALES NESTINA+ CON... 121K€ Cerrado

Duración del proyecto: 84 meses Fecha Inicio: 2016-11-07
Fecha Fin: 2023-11-30

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Atherosclerosis, the underlying cause of the majority of cardiovascular diseases (CVD), is a lipid driven, inflammatory disease of the large arteries. Despite a 25% relative risk reduction achieved by lipid-lowering treatment, the vast majority of atherosclerosis-induced CVD risk remains unaddressed. Therefore, characterizing mediators of the inflammatory aspect of atherosclerosis is a widely recognized scientific goal with great therapeutic implications. Co-stimulatory molecules are key players in modulating immune interactions. My laboratory has defined the co-stimulatory CD40-CD40L dyad as a major driver of atherosclerosis. Inhibition of CD40, and of its interaction with the adaptor molecule TRAF6 by genetic deficiency, antibody treatment or (nanoparticle based) small molecule inhibitor (SMI) treatment, is one of the most powerful therapies to reduce atherosclerosis in a laboratory setting. Although CD40-CD40L interactions are associated with adaptive immunity, I recently identified the macrophage as a driver of CD40-induced inflammation in atherosclerosis. We will use state-of-the-art in vitro experiments, live cell-, super resolution imaging, proteomics approaches and mutant mouse models to unravel the role of macrophage CD40 in atherosclerosis. Moreover, using structure based virtual ligand screening, I will develop lead SMIs targeting macrophage CD40-signaling, which I will deliver using macrophage-targeting nanoparticles. My goal is to define the role of macrophage CD40 in inflammation and immunity and disentangle how its activation affects atherosclerosis. I will finally test the feasibility of targeting macrophage CD40-signaling as a treatment for CVD. These studies will define the role of CD40-signaling in the innate immune system in health and (cardiovascular) disease. As components of macrophage CD40-signaling have the potential to be amenable to pharmacological manipulation, we will establish their feasibility as novel targets for (CVD) treatment.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores